Omnicell (OMCL) Reports In-Line Q4 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Omnicell (OMCL) Reports In-Line Q4 EPS

Omnicell Reports Fiscal Year and Fourth Quarter 2021 Results

February 14, 2022 4:01 PM EST

2021 Total Product Bookings of $1.217 billion

Full Year 2021 Revenues of $1.132 billion

Ended Year with 151 Long-Term, Sole-Source Agreements with the Top 300 U.S. Health Systems

Entered 2022 with Product Backlog of $1.254 billion

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Omnicell, Inc. (NASDAQ: OMCL) (Omnicell, we, our, us, management, or the Company), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its fourth quarter and fiscal year ended December 31, 2021.

GAAP Results

Total... More